233 related articles for article (PubMed ID: 25016096)
1. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
Tai TW; Su FC; Chen CY; Jou IM; Lin CF
Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells.
Tai TW; Chen CY; Su FC; Tu YK; Tsai TT; Lin CF; Jou IM
Sci Rep; 2017 Mar; 7():44245. PubMed ID: 28281643
[TBL] [Abstract][Full Text] [Related]
3. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.
Sutherland KA; Rogers HL; Tosh D; Rogers MJ
Arthritis Res Ther; 2009; 11(2):R58. PubMed ID: 19405951
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
5. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
7. The scaffold protein RACK1 mediates the RANKL-dependent activation of p38 MAPK in osteoclast precursors.
Lin J; Lee D; Choi Y; Lee SY
Sci Signal; 2015 Jun; 8(379):ra54. PubMed ID: 26038599
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
9. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of p38 MAPK mediates hypoxic preconditioning-induced neuroprotection against cerebral ischemic injury via mitochondria translocation of Bcl-xL in mice.
Zhao L; Liu X; Liang J; Han S; Wang Y; Yin Y; Luo Y; Li J
Brain Res; 2013 Mar; 1503():78-88. PubMed ID: 23399686
[TBL] [Abstract][Full Text] [Related]
11. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function.
Li X; Udagawa N; Itoh K; Suda K; Murase Y; Nishihara T; Suda T; Takahashi N
Endocrinology; 2002 Aug; 143(8):3105-13. PubMed ID: 12130576
[TBL] [Abstract][Full Text] [Related]
12. Ultraviolet A-induced modulation of Bcl-XL by p38 MAPK in human keratinocytes: post-transcriptional regulation through the 3'-untranslated region.
Bachelor MA; Bowden GT
J Biol Chem; 2004 Oct; 279(41):42658-68. PubMed ID: 15292226
[TBL] [Abstract][Full Text] [Related]
13. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
14. Control of late apoptotic events by the p38 stress kinase in L-glutamine-deprived mouse hybridoma cells.
Harnett CC; Guerin PJ; Furtak T; Gauthier ER
Cell Biochem Funct; 2013 Jul; 31(5):417-26. PubMed ID: 23080342
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro.
Huang X; Huang S; Guo F; Xu F; Cheng P; Ye Y; Dong Y; Xiang W; Chen A
Mol Med Rep; 2016 Jan; 13(1):613-22. PubMed ID: 26648136
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
18. Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice.
Lee EJ; Kim JL; Kim YH; Kang MK; Gong JH; Kang YH
Phytomedicine; 2014 Sep; 21(10):1208-15. PubMed ID: 24932975
[TBL] [Abstract][Full Text] [Related]
19. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
20. Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells.
Hou GQ; Guo C; Song GH; Fang N; Fan WJ; Chen XD; Yuan L; Wang ZQ
Int J Mol Med; 2013 Aug; 32(2):503-10. PubMed ID: 23740407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
